The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

About 1 in every 150 people infected develops severe symptoms that can affect the brain, spinal cord and nerves.

Riliprubart is an immunoglobulin G4 humanized antibody that is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system.

Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; ...

The Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid for the treatment of high-risk, Bacillus Calmette-Guérin ...

The scientist named on the slide, Robert Berman of the University of California-Davis, says he never wrote such a paper.

Researchers found that at week 24, 81 and 16% of the treated and control wounds, respectively, were at least 50% healed from baseline.

Vizamyl is now additionally indicated for use in a selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information.

HealthDay News — Fecal microbiota transplantation (FMT) could be considered as first-line therapy for primary Clostridioides difficile infection (CDI), according to a study published online June 17 in ...

The phase 3 trial evaluated fenfluramine when used as an adjunctive therapy for the treatment of uncontrolled seizures in children and adults aged 1 year to 35 years with CDD.

Michelle Bulls, director of the NIH’s Office of Policy for Extramural Research Administration, said no more grant cancellations should move forward.